Short Interest in Innovent Biologics, Inc. (OTCMKTS:IVBXF) Decreases By 20.3%

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 2,622,200 shares, a drop of 20.3% from the May 15th total of 3,291,500 shares. Based on an average daily volume of 4,100 shares, the short-interest ratio is presently 639.6 days.

Innovent Biologics Stock Up 6.0 %

Shares of IVBXF traded up $0.28 during mid-day trading on Monday, reaching $4.93. 24,800 shares of the stock traded hands, compared to its average volume of 153,267. Innovent Biologics has a 1 year low of $3.55 and a 1 year high of $6.41. The firm has a fifty day moving average price of $4.78 and a 200 day moving average price of $4.91.

About Innovent Biologics

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.